John Gyurci - 09 Mar 2026 Form 4 Insider Report for MiniMed Group, Inc. (MMED)

Role
Vice President, Chief Accounting Officer
Signature
/s/ Bryan F. Kelly, attorney-in-fact
Issuer symbol
MMED
Transactions as of
09 Mar 2026
Net transactions value
$0
Form type
4
Filing time
11 Mar 2026, 16:30:57 UTC
Previous filing
06 Mar 2026
Next filing
13 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gyurci John Vice President, Chief Accounting Officer C/O 18000 DEVONSHIRE STREET, NORTHRIDGE /s/ Bryan F. Kelly, attorney-in-fact 11 Mar 2026 0001850688

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MMED Performance-Based Restricted Stock Units Award +2,778 $0.000000* 2,778 09 Mar 2026 Common Stock 2,778 Direct F1, F2
transaction MMED Employee Stock Option (Right to Buy) Award +25,253 $0.000000* 25,253 09 Mar 2026 Common Stock 25,253 $18.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).
F2 The later of March 9, 2027 or the Divestment Date.
F3 The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

Remarks:

Vice President, Chief Accounting Officer